Matthew Witte, MD
Urology · Sioux Falls, SDNPI 1548228141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Boston Scientific at 28.9% of the total. 2025 is the largest year on record at $507, 2.8 times the $179 reported in 2019.
Across 66 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$478
- Procept Biorobotics Corporation$150
- Johnson & Johnson$144
- Janssen Scientific Affairs, LLC$108
- Endo Pharmaceuticals Inc.$77
- Innovation Technologies Inc$77
- plus $620 from 20 others
What the payments were for
- Food & beverage$1,49090%
- Education$16310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $478 |
| Procept Biorobotics Corporation | 2 | $150 |
| Johnson & Johnson | 4 | $144 |
| Janssen Scientific Affairs, LLC | 1 | $108 |
| Endo Pharmaceuticals Inc. | 5 | $77 |
| Innovation Technologies Inc | 2 | $77 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| 180 Medical, Inc. | 4 | $62 |
| Travere Therapeutics, Inc. | 15 | $56 |
| AstraZeneca | 2 | $53 |
| Histosonics, Inc. | 1 | $52 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $42 |
| Astellas Pharma US Inc | 2 | $39 |
| Merck | 2 | $34 |
| Organogenesis Inc. | 1 | $30 |
| Novo Nordisk | 1 | $23 |
| Medtronic | 1 | $19 |
| Laborie Medical Technologies Corp. | 2 | $19 |
| Palette Life Sciences, Inc. | 1 | $17 |
| Myovant Sciences Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Coloplast | 1 | $15 |
| Bayer | 1 | $13 |
| Convatec Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
| Urogen Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$125
- ADVANCE$111
- Erleada$108
- ZYTIGA$108
How this compares
$1,654 in reported general payments places this provider in the 70th percentile of 40 urology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 74 | $45,726 |
| GemtesaVibegron | 16 | $8,462 |
| Potassium Citrate ErPotassium Citrate | 87 | $6,465 |
| Dutasteride | 125 | $4,187 |
| Tamsulosin Hcl | 340 | $3,906 |
| Finasteride | 292 | $2,712 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 24 | $1,410 |
| Silodosin | 28 | $1,365 |
| Methenamine Hippurate | 17 | $980 |
| Oxybutynin Chloride ErOxybutynin Chloride | 30 | $588 |
| Solifenacin Succinate | 22 | $450 |
| Terazosin Hcl | 16 | $193 |
| Cefdinir | 16 | $160 |
| Cephalexin | 35 | $150 |
| Levofloxacin | 47 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $39 | $45,72674 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $75 | $8,46216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 40 urology providers in South Dakota.
Other urology in Sioux Falls
- Lauren ThumSioux Falls$7K
- Eugene ParkSioux Falls$2K
- Nathan BockholtSioux Falls$2K
- Dennis ThumSioux Falls$2K
- Brian LindamanSioux Falls$1K
- Matthew LarsonSioux Falls$1K
- Darlys HoferSioux Falls$1K
- David ArendSioux Falls$948
- Michael GillettSioux Falls$713
- Alex HannemannSioux Falls$645
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.